Under new approval, the drug can be given with immunotherapy to help reduce risk of recurrence after surgery in patients with clear cell renal cell carcinoma. The U.S. Food and Drug Administration (FDA) has...
AACR grant recipient Tae Hyun Hwang, PhD, of Vanderbilt University Medical Center, presented his work at the AACR Annual Meeting 2026 on AI agents that work together to assess how patients could respond to therapy and aid doctors in making cancer treatment decisions.
A targeted therapy nearly doubles overall survival in metastatic pancreatic cancer, and the FDA approves a bladder cancer treatment.
At the AACR Annual Meeting 2026, Lillian Siu shared her research into cancer interception and assembled a panel to discuss targeted cancer prevention.
At the AACR Annual Meeting 2026, researchers discussed the use of vaccines and aspirin to prevent cancer in people with Lynch syndrome.
ACS colorectal cancer screening guideline now includes a blood-based test, and GLP-1 therapies may reduce risk for cancer progression.
The FDA approved durvalumab with Bacillus-Calmette Guérin for patients with high-risk, BCG-naïve non-muscle invasive bladder cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with Bacillus Calmette-Guérin (BCG) for...
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and pancreatic cancer, and more.
The FDA approved pivekimab sunirine-pvzy for the treatment of the rare blood cancer BPDCN. The U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine-pvzy (Decnupaz) for the treatment of adult patients with blastic...
Datopotamab deruxtecan-dlnk was approved to treat PD-1/PD-L1 inhibitor-ineligible, advanced triple-negative breast cancer. The U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adults with unresectable or metastatic triple-negative breast cancer (TNBC)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More